Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial

Autor:	V. Distante, R. Franchi, Matteo Puntoni, Mario Mesiti, Francesco Boccardo, Alessandra Rubagotti, M. Porpiglia, Pamela Guglielmini, Michela Rinaldini, G. Paladini
Rok vydání:	2005
Předmět:	Oncology Gynecology Cancer Research medicine.medical_specialty business.industry Anastrozole stomatognathic diseases Internal medicine medicine skin and connective tissue diseases business Tamoxifen Early breast cancer medicine.drug
Zdroj:	Journal of Clinical Oncology. 23:526-526
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.526
Popis:	526 Background: We have previously shown that switching to ANA after 2–3 years of TAM is well tolerated and significantly improves event-free (EFS) and progression-free survival (PFS) of postmenopa...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::16a7bb1534ee188e8f86516519d7f305 https://doi.org/10.1200/jco.2005.23.16_suppl.526 Zobrazit plný text záznamu